Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

Investigating the Therapeutic Potential of NLRC5 to Restore MHC Class I Expression and Diversity in Ovarian Cancer Cells

FY 2023-24

Summary
Ovarian cancer is the most lethal gynecological cancer. Every year in Canada, 3000 patients will be diagnosed and only 45% will survive for at least five years. These low survival rates are thought to be due to two main reasons: a lack of effective screening tools and ineffective treatment options. Current treatment of ovarian cancer involves a combination of chemotherapy and surgery; however recurrence is common. Immunotherapies are effective in 15% of patients. Therefore, there is a need for new, better treatments for ovarian cancer. When a foreign entity is detected by a healthy cell, the cell will process it and display it to the immune system on proteins called Major Histocompatibility Complex (MHC) Class I molecules. This display to CD8+ T cells of the immune system results in T cell activation, allowing the T cells to kill the infected cells before the disease can spread. However, MHC I is downregulated/lost in 60% of all ovarian cancers. My project aims to develop a method to recover this lost expression, using a protein called NLRC5. NLRC5 is a driver of MHC I expression. To introduce more NLRC5 into ovarian cancer cells, we are inserting the NLRC5 gene into a virus called Modified Vaccinia Ankara virus (MVA). MVA is a virus that has been engineered to be non-replicating in most mammalian cells, and is known to favour the reproductive tract. This makes the virus very useful for our purposes as it can enter and deliver NLRC5 into ovarian cancer cells without killing cancerous or healthy cells directly. By forcing the cancer cells to make MHC I, we predict that they will now be better able to activate the T cells so that they can respond to immunotherapies.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
506037
Name
Fletcher Erin L
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the Therapeutic Potential of NLRC5 to Restore MHC Class I Expression and Diversity in Ovarian Cancer Cells
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Immunotherapy; Mhc I; Nlrc5; Ovarian Cancer; Vaccinia Virus
Abstract
Ovarian cancer is the most lethal gynecological cancer. Every year in Canada, 3000 patients will be diagnosed and only 45% will survive for at least five years. These low survival rates are thought to be due to two main reasons: a lack of effective screening tools and ineffective treatment options. Current treatment of ovarian cancer involves a combination of chemotherapy and surgery; however recurrence is common. Immunotherapies are effective in 15% of patients. Therefore, there is a need for new, better treatments for ovarian cancer. When a foreign entity is detected by a healthy cell, the cell will process it and display it to the immune system on proteins called Major Histocompatibility Complex (MHC) Class I molecules. This display to CD8+ T cells of the immune system results in T cell activation, allowing the T cells to kill the infected cells before the disease can spread. However, MHC I is downregulated/lost in 60% of all ovarian cancers. My project aims to develop a method to recover this lost expression, using a protein called NLRC5. NLRC5 is a driver of MHC I expression. To introduce more NLRC5 into ovarian cancer cells, we are inserting the NLRC5 gene into a virus called Modified Vaccinia Ankara virus (MVA). MVA is a virus that has been engineered to be non-replicating in most mammalian cells, and is known to favour the reproductive tract. This makes the virus very useful for our purposes as it can enter and deliver NLRC5 into ovarian cancer cells without killing cancerous or healthy cells directly. By forcing the cancer cells to make MHC I, we predict that they will now be better able to activate the T cells so that they can respond to immunotherapies.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Fletcher, Erin L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~